DNA Methylation Profiling in Melanoma: From Lesion Classification to Therapeutic Stratification

📅 2026-08-19
📈 Citations: 0
Influential: 0
📄 PDF
🤖 AI Summary
研究使用DNA甲基化分析方法,通过机器学习模型区分不同类型的黑色素瘤病变,并预测临床治疗组别,为诊断和疾病分层提供信息。
📝 Abstract
DNA methylation provides a stable record of cellular identity, capturing epigenetic programs that distinguish specialized cell states despite a shared genome. Because malignant transformation and tumour progression are accompanied by extensive epigenetic remodeling, we hypothesized that the methylome of melanocytic lesions contains biologically and clinically relevant information for both diagnosis and disease progression. In a cohort of 1,001 tissue samples prospectively collected across eight German university hospitals profiled using Illumina Infinium MethylationEPIC arrays, we compared machine-learning models based on selected Cytosine phosphate Guanine (CpG) methylation sites with models incorporating biology-guided features, including epigenetic age acceleration, cell type composition and copy-number variation burden. In an external test set, the best diagnostic classifier was CpG-based and distinguished melanocytic nevi, noninvasive melanoma and invasive melanoma with a macro-averaged area under the receiver operating characteristic curve of 0.919 (95% CI: 0.878 to 0.952). Notably, across CpGs most strongly hyper- and hypomethylated between NV and IM, NIM showed an intermediate methylation profile, providing a molecular correlate of its diagnostic complexity. The best model for clinically relevant treatment group prediction, with AJCC stages grouped according to guideline-based management recommendations, relied on biology-guided features and achieved a macro-averaged mean absolute error of 0.627 (95% CI: 0.477 to 0.808). Together, these findings demonstrate that methylation-based models can capture both diagnostic identity and clinically relevant disease stratification, supporting DNA methylation as a promising biomarker for further validation and potential clinical translation.
Problem

Research questions and friction points this paper is trying to address.

DNA Methylation
Melanoma
Lesion Classification
Therapeutic Stratification
Biomarker
Innovation

Methods, ideas, or system contributions that make the work stand out.

DNA methylation
CpG methylation sites
machine-learning models
diagnostic classifier
biologically guided features
🔎 Similar Papers
No similar papers found.
J
Jana T. Winterstein
Division of Digital Prevention, Diagnostics and Therapy Guidance, German Cancer Research Center (DKFZ), INF 223, 69120 Heidelberg, Germany; Medical Faculty, University Heidelberg, Heidelberg, Germany
L
Lukas Heinlein
Division of Digital Prevention, Diagnostics and Therapy Guidance, German Cancer Research Center (DKFZ), INF 223, 69120 Heidelberg, Germany; Medical Faculty, University Heidelberg, Heidelberg, Germany
G
Günter Raddatz
Department of Epigenetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
C
Carina Nogueira Garcia
Division of Digital Prevention, Diagnostics and Therapy Guidance, German Cancer Research Center (DKFZ), INF 223, 69120 Heidelberg, Germany
S
Sarah Haggenmüller
Division of Digital Prevention, Diagnostics and Therapy Guidance, German Cancer Research Center (DKFZ), INF 223, 69120 Heidelberg, Germany
C
Christoph Wies
Division of Digital Prevention, Diagnostics and Therapy Guidance, German Cancer Research Center (DKFZ), INF 223, 69120 Heidelberg, Germany; Medical Faculty, University Heidelberg, Heidelberg, Germany
L
Lucas Schneider
Division of Digital Prevention, Diagnostics and Therapy Guidance, German Cancer Research Center (DKFZ), INF 223, 69120 Heidelberg, Germany
A
Annemarie Hoffsommer
Division of Digital Prevention, Diagnostics and Therapy Guidance, German Cancer Research Center (DKFZ), INF 223, 69120 Heidelberg, Germany; Medical Faculty, University Heidelberg, Heidelberg, Germany
T
Tim J. Zeuner
Division of Digital Prevention, Diagnostics and Therapy Guidance, German Cancer Research Center (DKFZ), INF 223, 69120 Heidelberg, Germany; Medical Faculty, University Heidelberg, Heidelberg, Germany
F
Friedegund Meier
Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany, Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases Dresden, Dresden, Germany
S
Sarah Hobelsberger
Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany, Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases Dresden, Dresden, Germany
F
Frank F. Gellrich
Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany, Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases Dresden, Dresden, Germany
M
Mildred Sergon
Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany, Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases Dresden, Dresden, Germany
A
Axel Hauschild
Department of Dermatology, University Hospital (UKSH), Kiel, Germany
L
Lucie Heinzerling
Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany; Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg; Comprehensive Cancer Center Erlangen – European Metropolitan Region Nürnberg, CCC Alliance WERA, Erlangen; Bavarian Cancer Research Center (BZKF), Erlangen, Germany
J
Justin G. Schlager
Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany
K
Kamran Ghoreschi
Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
M
Max Schlaak
Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Vivantes Hospital Spandau, Department of Dermatology and Allergology, Berlin, Germany
F
Franz J. Hilke
Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
C
Carola Berking
Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg; Comprehensive Cancer Center Erlangen – European Metropolitan Region Nürnberg, CCC Alliance WERA, Erlangen; Bavarian Cancer Research Center (BZKF), Erlangen, Germany
M
Markus V. Heppt
Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg; Comprehensive Cancer Center Erlangen – European Metropolitan Region Nürnberg, CCC Alliance WERA, Erlangen; Bavarian Cancer Research Center (BZKF), Erlangen, Germany; Dermpath München, Laboratory for Dermatopathology, Oral Pathology and Molecular Pathology, Munich, Germany
M
Michael Erdmann
Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg; Comprehensive Cancer Center Erlangen – European Metropolitan Region Nürnberg, CCC Alliance WERA, Erlangen; Bavarian Cancer Research Center (BZKF), Erlangen, Germany
S
Sebastian Haferkamp
Department of Dermatology, University Hospital Regensburg, Regensburg, Germany
K
Konstantin Drexler
Department of Dermatology, University Hospital Regensburg, Regensburg, Germany
Dirk Schadendorf
Dirk Schadendorf
Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany